Allergy Therapeutics plc (AGYTF)
OTC PINK OTC PINK Primary 
Grass MATA & peanut vaccine development to drive Allergy Therapeutics - ICYMI
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive about the company's financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control.
Allergy Therapeutics: The financial recovery continues, says broker
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is starting to find its feet again, with broker Cavdenidsh noting the 'financial recovery continues' with its analysis of first-half results. The immunology specialist posted interim results on Monday showing revenue of £34 million for the six months to 31 December.
Allergy Therapeutics builds momentum as pipeline progresses
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) expects sales growth to pick up in the second half of the year and has reiterated plans to launch its new grass pollen vaccine, Grass MATA MPL once it secures regulatory approval in Germany. If greenlit by the Paul-Ehrlich-Institut (PEI), the short-course hay fever treatment could be on the market by this time next year, analysts reckon.
Allergy Therapeutics hits dosing milestone in peanut allergy vaccine trial
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has reached a key milestone in the clinical development of its peanut allergy vaccine with healthy volunteers now receiving the highest planned doses and no safety issues reported. The AIM-listed biotech said on Thursday that the final phase of its Phase I/IIa PROTECT trial is underway, with its vaccine candidate, known as VLP Peanut, being tested at doses beyond the expected therapeutic range.
Allergy Therapeutics updates on progress at international event
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is set to present its latest research at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization (AAAAI/WAO) Joint Congress, which is taking place in San Diego from 28 February to 3 March. The event brings together clinicians and researchers focused on allergy, asthma, and immunology.
Allergy Therapeutics hails key validation of grass allergy treatment
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) says the latest publication of phase III trial data provides important validation of its treatment, Grass MATA MPL. The findings, shared in the journal Allergy, confirm the effectiveness of the company's short-course immunotherapy for grass pollen allergies.
Allergy Therapeutics 'building momentum' as sales and volumes recover
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) said it is back on track and growing again after the financial and operational challenges of recent years. Interim revenues to 31 December 2024 are expected to be £34 million, up by 2% and the second consecutive half of growth, with volumes up by 5% as its manufacturing capability recovers after the previous disruption.
Allergy Therapeutics: A story of resilience and transformation
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) is writing a story of resilience and transformation. Putting behind it manufacturing setbacks, the company has redefined its trajectory with a bold strategy centred on innovation.
Allergy Therapeutics unveils encouraging early data from peanut trial
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has announced encouraging interim findings from its phase I/IIa VLP Peanut PROTECT trial aimed at addressing peanut allergies using a nanoparticle-based treatment. The study's early data shows that VLP Peanut could reduce sensitivity to peanuts and lower allergic reactions.
Allergy Therapeutics begins paediatric trial for grass allergy treatment
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has commenced a phase III trial to test the long-term safety and effectiveness of its Grass MATA MPL allergy treatment in children. This marks the first industry trial of its kind for paediatric patients with grass pollen-induced allergic rhinitis.
Allergy Therapeutics applies for full marketing approval for grass allergy jab
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) marked a 'significant milestone' after it applied for regulatory approval of its new grass allergy immunotherapy. The submission, made to Germany's Paul Ehrlich Institut (PEI), includes evidence from a phase III clinical trial showing significant symptom reduction during peak pollen season.
